Please login to the form below

Not currently logged in
Email:
Password:

J&J and Elan close deal

J&J and Elan agree deal for Alzheimer's Immunotherapy Programme and investment plan

Johnson & Johnson's (J&J) newly formed subsidiary Janssen Alzheimer Immunotherapy has acquired all the assets and rights of Elan related to its Alzheimer's Immunotherapy Programme (AIP).

As part of the deal, through its affiliate Janssen Pharmaceutical, J&J has invested $885m in exchange for newly issued American Depositary Receipts (ADRs) of Elan, which represents 18.4 per cent the firm's outstanding ordinary shares.

The AIP represents Elan's interest in a collboration with Wyeth Pharmaceuticals to research, develop and commercialise selective products for the treatment and/or prevention of neurodegenerative conditions, including Alzheimer's disease.

Janssen Alzheimer Immunotherapy will take over Elan's activities with Wyeth under the terms of the AIP and will develop activities for bapineuzumab, a potential first-in-class treatment being evaluated for slowing the progress of Alzheimer's.

The AIP includes multiple compounds being evaluated for slowing the progression of the disease. Lead compound, bapineuzumab, administered intravenously once every three months, is currently in phase III trials. In addition, a subcutaneous formulation administered once a week is in phase II trials, as is a vaccine for Alzheimer's.

17th September 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics